Midostaurin (PKC412)

For research use only.

Catalog No.S8064 Synonyms: CGP 41251

17 publications

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
USD 3990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Midostaurin (PKC412) has been cited by 17 publications

2 Customer Reviews

  • (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.

    Leukemia, 2018, 32(1):139-148. Midostaurin (PKC412) purchased from Selleck.

  • PKC412 is cytotoxic to human HNSCC cells. The established HNSCC cells (SQ20B and SCC‐9 cell lines), primary human oral carcinoma cells (“Primary1/2”) and primary oral epithelial cells (“Epithelial”), were treated with indicated concentrations of PKC412. Cells were then cultured in complete medium for the applied time, and cell survival was tested by the MTT assay (a, d) and colony formation assay (c). Cell death was tested by the trypan blue staining assay (b). “CTR” indicates medium‐treated control group (for all figures). All the experiments were repeated five times, and similar results were obtained. n = 5 for each assay. Error bars indicate mean ± SD (for all figures). *p < 0.05 versus group “CTR.” HNSCC, head and neck squamous cell carcinoma; MTT, 3‐(4,5‐dimethyl‐thiazol-2-yl)2,5-diphenyl tetrazolium bromide; OD, optical density; PKC, protein kinase C

    J Cell Physiol, 2018, 233(12):9437-9446. Midostaurin (PKC412) purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MUXDfZRwfG:6aXPpeJkh[XO|YYm= M2fETVczKGh? MmPZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk\WyuIITpeIVzNWKudXWgZZN{[XluIFnDOVA:OTJibl2= MVOxPVY2PDRyOB?=
RS4-11 cells NF\5RXFHfW6ldHnvckBie3OjeR?= Ml65NkBp M3X5dWlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3ME2xN{BvVQ>? M3LKOFE6PjV2NEC4
CGTH-W-1 cell M1fKd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYjFcVE1UW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR{Lk[1JO69VQ>? MWfTRW5ITVJ?
SW982 cell NETzRoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml\nTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1MlU5KM7:TR?= M1;CNnNCVkeHUh?=
human EoL-1-cell cell MkDZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH3KdldKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Mj6wPEBvVQ>? NFrLdZhUSU6JRWK=
MOLM-13 cells MkP6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHiO|IhcA>? NXHUVnNDUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDo[ZRmem:8eXfveZMhdXW2YX70JIlvKGi3bXHuJG1QVE1vMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvODV3IN88US=> NWC2[G5qOjZyOEGwNlM>
KASUMI-1 cell M1LaW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M133bGlvcGmkaYTpc44hd2ZiaIXtZY4hU0GVVV3JMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MEG2JO69VQ>? NWK0TFFbW0GQR1XS
NCI-H1755 cell M4HKNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvnXlFHUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkC2Nlc{KM7:TR?= MUHTRW5ITVJ?
human MES-SA cell MorUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUO2OpJCUW6qaXLpeIlwdiCxZjDoeY1idiCPRWOtV2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB5NUS0JO69VQ>? NVrJZm9qW0GQR1XS
human HCC1395 cell NH;1UYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PDJ6IN88US=> NH3DNoRUSU6JRWK=
human D-336MG cell NHfSPZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=> NX7CdINRW0GQR1XS
CHP-212 cell M3W5eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVfJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5Pzd|IN88US=> NVnpU2hNW0GQR1XS
human KM12 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHxc3ZKdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA6Ojd3IN88US=> MmXvV2FPT0WU
A204 cell MmrRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHLxW41KdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExODV{IN88US=> M13IbXNCVkeHUh?=
CAL-51 cell MmfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVA4ODlizszN NX;udpR6W0GQR1XS
human A431 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIDFb3JKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOjF4IN88US=> MnXwV2FPT0WU
NCI-H650 cell M4S4cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVzJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTdyODFOwG0> NULGVm9XW0GQR1XS
A427 cell NWqxOWtzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWD6fGI{UW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTlzODFOwG0> MV;TRW5ITVJ?
human 769-P cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXLSNJhXUW6qaXLpeIlwdiCxZjDoeY1idiB5NkmtVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJyOEKg{txO NHHjRoZUSU6JRWK=
SW1710 cell Mn7IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM{OTZizszN Mkf0V2FPT0WU
human H4 cell MljQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXrjSVE5UW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVM6PjNizszN NYDiRVVbW0GQR1XS
HT-1080 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\EUoVbUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NkDPxE1? NG\5cXdUSU6JRWK=
human PANC-03-27 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NELQeGZKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFIh|ryP NIThVoxUSU6JRWK=
A375 cells MWjDfZRwfG:6aXPpeJkh[XO|YYm= NESxXIk4OiCq M{jB[nRwgGmlaYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBKSzVyPUCuNVgh|ryP MoHkNVk3PTR2MEi=
human HOP-62 cell NI\wOJpHfW6ldHnvckBie3OjeR?= NFv4O4NKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO NHTNNJlUSU6JRWK=
human U031 cell NGTlZ4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1rHV2lvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk3QThizszN NIjHcWxUSU6JRWK=
mouse BAF3 cells MmexVJJwdGmoZYLheIlwdiCjc4PhfS=> NEWxXXhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgeJJidnOob4Lt[YQhf2m2aDDaUmYyQThvRlfGVlEh[2:wc4TyeYN1NCCLQ{WwQVAvOiEQvF2= NUHWRWloOjF7M{[1OFI>
human G-402 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml7iTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlAzPTNizszN M{naOnNCVkeHUh?=
human G-361 cell NH7EVnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFg2OyEQvF2= M{PXRXNCVkeHUh?=
NCI-H810 cell M4jOcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIrvRVBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IPFExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MUCyO{DPxE1? MmTNV2FPT0WU
NCI-H2030 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4\zb2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{CwOkDPxE1? M17jfXNCVkeHUh?=
human HCT-116 cell NITjOoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3rLSGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO M4PGTXNCVkeHUh?=
human SNU-423 cell Ml2wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS12MkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PjV5IN88US=> NGC4V4NUSU6JRWK=
human SCC-4 cell NY[xcZFJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NE[zc5NKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOzl4NzFOwG0> NFHjSVJUSU6JRWK=
human SW48 cell M135[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHjJZWFKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI3PjhizszN MoG1V2FPT0WU
human SF295 cell NX\O[ZBjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGXKPZZKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzJ3NzFOwG0> MXrTRW5ITVJ?
MDA-MB-231 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWrhU4RDUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPFExOSEQvF2= NWrkWFk3W0GQR1XS
A172 cell NIjCboFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGi2XY5KdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6OTVizszN MXPTRW5ITVJ?
human BCPAP cell NIfKSZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFi1NY5KdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTh5OTFOwG0> M1P3TnNCVkeHUh?=
human COLO-792 cell NH:4XHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2j6b2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ7OUeyJO69VQ>? MnPFV2FPT0WU
human DU-145 cell MoXWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYL6epc1UW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzOEi5JO69VQ>? MmryV2FPT0WU
NCI-H2122 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO MlzoV2FPT0WU
human SK-UT-1 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFjSNZdKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{OUWyJO69VQ>? MkDvV2FPT0WU
LXF-289 cell Mn:xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTZ3IN88US=> NFLIc45USU6JRWK=
human NCI-H1792 cell NX73NmFlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MojVTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MEm2JO69VQ>? MV\TRW5ITVJ?
MCF7 cell M2L6UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIDxcXRKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{Ojd2IN88US=> MX\TRW5ITVJ?
HCT-15 cell NEix[XlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M1OzJizszN MW\TRW5ITVJ?
human NCI-H358 cell NX7KUHhRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KM{W4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzV3MTFOwG0> MnrHV2FPT0WU
human HLE cell NVXMdGlLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhNTSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{O3OVIh|ryP NGnqV5BUSU6JRWK=
human SW1088 cell NGPwNY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4QTdizszN Mn3sV2FPT0WU
human K5 cell M3PhNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3[xWWlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO2NVQ6KM7:TR?= MYrTRW5ITVJ?
human SR cell NX3hNYJsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLjZ2xKdmirYnn0bY9vKG:oIHj1cYFvKFOUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlU4OSEQvF2= MnjqV2FPT0WU
human Calu-3 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y5OjVizszN NX7ZSGg6W0GQR1XS
human SK-MEL-30 cell NXrWNWprT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl7MUOg{txO NIX3XpZUSU6JRWK=
human SW780 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFrkfVdKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0> M2rKWXNCVkeHUh?=
NCI-H1563 cell NXvqbmM{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDF2OESg{txO NGH4WXJUSU6JRWK=
human MKN45 cell NFfYTItIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGXxRVRKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTl|MTFOwG0> MXXTRW5ITVJ?
MDA-MB-157 cell MkXyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MljNTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkCxOUDPxE1? M3zyTHNCVkeHUh?=
human NCI-H522 cell M3\sTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;xV5NrUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKzJO69VQ>? MV;TRW5ITVJ?
human A2780 cell M3zlbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYXidVQxUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDd3MEOg{txO NXXjbng5W0GQR1XS
human A498 cell NFzGfVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2jzUGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc3QTNizszN M2PUcHNCVkeHUh?=
human BxPC-3 cell NH7zW4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH7y[45KdmirYnn0bY9vKG:oIHj1cYFvKEK6UFOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDl|Nk[g{txO MkPRV2FPT0WU
human A2058 cell NYjNVoZHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTIU|JuUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTJ6NESg{txO MVLTRW5ITVJ?
human PC-14 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFjTW29KdmirYnn0bY9vKG:oIHj1cYFvKFCFLUG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42Ozh3NTFOwG0> NFX2dlJUSU6JRWK=
human KG-1 cell NFe2bHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvjfWtKdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU2PDF7IN88US=> MkHKV2FPT0WU
human A375 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfkUVhKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU3OTB|IN88US=> NXvsfXZJW0GQR1XS
human SW1783 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MonITY5pcWKrdHnvckBw\iCqdX3hckBUXzF5OEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{OzdizszN MUDTRW5ITVJ?
human MKN1 cell NX\UWJNPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLJcohq[mm2aX;uJI9nKGi3bXHuJG1MVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4OFEzKM7:TR?= NIXPTnlUSU6JRWK=
NCI-H1650 cell NH;oSJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYKydphVUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki4PVE364DCzszN NHLKSm1USU6JRWK=
human HT-1376 cell NFvFOGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXLIZlZzUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xN|c3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MkmxPEDPxE1? NGiwb3dUSU6JRWK=
SW872 cell NED6O4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PUUWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1PDV7IN88US=> M3K2R3NCVkeHUh?=
human RT-112 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3kTY5pcWKrdHnvckBw\iCqdX3hckBTXC1zMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4PDh|IN88US=> MX;TRW5ITVJ?
human HT-29 cell NXzXUZNsT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFHOPYVKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46Pzl7NjFOwG0> NVvZ[mZnW0GQR1XS
human U-266 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJHUuOjZ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65PFMxOiEQvF2= MYrTRW5ITVJ?
human HEL cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHvX[HRKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg2OTdizszN Mnj6V2FPT0WU
human KU812 cell NWS0Xmp{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUmzV45KUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTFzNkSg{txO M1PFT3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-TYR / p-STAT5 / STAT5 / p-S6 / S6 / p-MAPK / MAPK / p-AKT / AKT ; 

PubMed: 28881711     


Effect of midostaurin and PRT062607 on TEL-SYK phosphorylation and phosphorylation of downstream effectors following 2 hr of treatment. For the experiment analyzing effects of midostaurin and PRT062607 on phosphorylation of TEL-SYK, SYK immunoprecipitation was carried out prior to immunoblotting with a PTYR (4G10) antibody. Immunoblotting was performed for the experiment analyzing effects of midostaurin and PRT062607 on signaling molecules downstream of TEL-SYK. Relative densitometry readings for pMAPK/total MAPK (normalized to control lane) are as follows: 0 nM midostaurin=1.0, 10 nM midostaurin=0.93, 100 nM midostaurin=0.41, 1000 nM midostaurin=0.04, 0 nM PRT062607=1.0, 10 nM PRT062607=0.72, 100 nM PRT062607=0.37, 1000 nM PRT062607=0.07. 

PKCα / PKCβ1 / PKCβ2 / PKCγ / PKCη / p-PKC / p-Bad / Bad / p-Bcl2 / Bcl-2 / p-p65 / p65; 

PubMed: 30584254     


The indicated PKC isoforms were up-regulated in the resistant BL cells, leading to elevated levels of PKC phosphorylation and the activation of downstream anti-apoptotic proteins.

28881711 30584254
In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
- Collapse
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03951961 Not yet recruiting Drug: Midostaurin Acute Myeloid Leukemia Adult Sebastian Scholl PD Dr. med.|Ludwig-Maximilians - University of Munich|University of Jena May 1 2020 Phase 2
NCT04097470 Recruiting Drug: Decitabine|Drug: Midostaurin AML/MDS Stichting Hemato-Oncologie voor Volwassenen Nederland|Swiss Group for Clinical Cancer Research December 5 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy PKC412|PKC412 ic50|PKC412 price|PKC412 cost|PKC412 solubility dmso|PKC412 purchase|PKC412 manufacturer|PKC412 research buy|PKC412 order|PKC412 mouse|PKC412 chemical structure|PKC412 mw|PKC412 molecular weight|PKC412 datasheet|PKC412 supplier|PKC412 in vitro|PKC412 cell line|PKC412 concentration|PKC412 nmr|PKC412 in vivo|PKC412 clinical trial|PKC412 inhibitor|PKC412 Cytoskeletal Signaling inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID